Over 11 million adults were prescribed addictive drugs between 2017 and 2018 in England, according to a major new review by public health officials.
The Public Health England (PHE) review, which looked at data for five commonly prescribed medicines – antidepressants, opioids, gabapentinoids, benzodiazepines and z-drugs – found that 26% of adults in England received a prescription for one or more of these drugs in the 12 months prior to March 2018.
GP leaders have said it is ‘encouraging’ the review shows a decline in opioid prescriptions for chronic pain, and also welcomed the report’s call for more support services to help GPs and patients manage withdrawal in the community.
The PHE review said it was ‘difficult to determine’ the prevalence of dependence on, or withdrawal from, the medicines covered in the review.
However, it concluded the data on the duration of prescribing suggests that dependence and withdrawal are ‘likely to be significant issues, particularly when seen together with the significant concerns raised by some patients, campaigners and others’.
Regular reviews needed
The data showed that in March 2018, among all those people in receipt of a prescription, around half of patients for each medicine type were estimated to have been receiving a prescription continuously for at least 12 months.
While long-term prescribing may be clinically appropriate for some patients, the review stressed the importance of regular reviews to avoid people developing dependence or experiencing withdrawal.
‘Patients may come to medical appointments with a clear expectation that medicines will meet their needs, and some will assertively make a case to receive a prescription. Increased awareness among the public and clinicians of treatments that are alternative, or supplementary, to medicines, and of the risks and benefits of medicines, is vital,’ said the report.
The data analysed for the review also showed prescribing rates and the length of prescriptions were higher in more deprived areas of the country.
GPs ‘under pressure’ to prescribe
PHE admitted that GPs in these regions were under ‘great pressure’ to prescribe drugs, and said alternative treatments needed to be considered.
Rosanna O’Connor, director of alcohol, drugs, tobacco and justice at PHE, said: ‘We know that GPs in some of the more deprived areas are under great pressure but, as this review highlights, more needs to be done to educate and support patients, as well as looking closely at prescribing practice and what alternative treatments are available locally.
‘While the scale and nature of opioid prescribing does not reflect the so-called crisis in North America, the NHS needs to take action now to protect patients.’
Commenting on today’s findings, Dr Andrew Green, who represented the BMA during PHE’s drug review, said: ‘Doctors in the UK are of course concerned at the number of patients being prescribed these medicines, and the length of time they are taking them for.
‘While there isn’t a single cause for high prescription rates, social deprivation, an increased prevalence of mental health problems and poor access to mental health care, a rise in the demand for GP services and a growing, aging population, are likely to be significant contributing factors.’
He added: ‘It is positive that this report recognises that to reduce prescription levels, we need significant investment in support services; this will enable patients and GPs to manage dependencies together in the community. GPs will often be the sole clinicians who are managing a patient’s withdrawal, and there is a real need for better clinical guidance in this respect. We are glad that NICE is in the process of developing this.’
Majority of scripts short-term
Professor Helen Stokes-Lampard, chair of the RCGP, said: ‘This report analyses prescribing data for medications that when prescribed appropriately can be effective and beneficial for many patients – and it shows that the vast majority of prescriptions issued are short term, and that we are seeing a decline in opioid prescriptions for chronic pain, both of which are encouraging trends.
‘What it also indicates is the severe lack of alternatives to drug therapies for many conditions – and where effective alternatives are known and exist, inadequate and unequal access to them across the country.’
Want news like this straight to your inbox?
Dr Richard Vautrey, former chair of the BMA GP committee, has been appointed to sit...
ICSs have overspent by £651m in the first six months of the financial year against...